Abstract: Pol ? protein inhibitor compounds are useful for selectively inhibiting the growth of MLH1 mutant/deficient tumor or cancer cells due to a synthetic lethal relationship between MLH1 and Pol ?. The compounds were shown to directly interact with Pol ? and inhibit its biological function and cause cancer cell death and an inhibition of tumor or cancer cell growth in multiple assays.

Abstract: The present invention relates to a method for calculating a personal reference range in order to compare results of a measurement carried out in case of suspicion of an illness, by using results of persons'laboratory tests measured in a period when they feel healthy.

Abstract: Pol ? protein inhibitor compounds are useful for selectively inhibiting the growth of MLH1 mutant/deficient tumor or cancer cells due to a synthetic lethal relationship between MLH1 and Pol ?. The compounds were shown to directly interact with Pol ? and inhibit its biological function and cause cancer cell death and an inhibition of tumor or cancer cell growth in multiple assays.

Abstract: The present invention is a solution for preservation of organs prior to organ transplantation used in reducing the damage occurring during transportation and waiting of liver and kidney prior to transplantation. Accordingly, the subject matter solution is characterized by comprising Raffinose in the range of 25-35 mmol/L, Lactobionate in the range of 80-120 mmol/L, HES (Hydroxy-ethyl starch) in the range of 0-4% g, SO42? in the range of 4.5-5.5 mmol/L, Adenosine in the range of 4.5-5.5 mmol/L, Glutathione in the range of 2.7-3.3 mmol/L, Allopurinol in the range of 0.9-1.1 mmol/l, Na+ in the range of 27-33 mmol/L, K+ in the range of 115-125 mmol/L, Mg+ in the range of 4.5-5.5 mmol/L, Histidine/Histidine-HCl in the range of (25-30)/(2.5-3.0) mmol/L, Melatonin in the range of 30-50 mg/L, Glucosamine in the range of 20-100 mg/L.